What updates have occurred in the Neurodegenerative disease field as of late? New appointments by the Dementia Discovery Fund, which widens its international reach – and new ‘out of the box’ ideas from Israel and South Korea.
The Dementia Discovery Fund (DDF), an innovative global investment fund managed by SV Life Sciences and launched in October to discover and develop new disease modifying drugs for dementia, announces the appointment of a new CSO.
This comes with additional major news in the Alzheimer’s and Dementia research field since we wrote our 2015 review in November. For example, as published in December in Nature, researchers at the Weizmann Institute (Israel) have been investigating the use of anti-cancer compounds (PD-L1 checkpoint inhibitors) to tackle the toxic amyloid-β (Aβ) plaques the disease to good result.
This is certainly a novel approach to Alzheimer’s treatments, which have already a rather broad target range in the field.